Sulfiredoxin (SRXN1) was previously found to be associated with cerebrovascular disease in a Finnish cohort [41], and SRXN1 genetic polymorphisms were associated with breast cancer risk and survival [42]. This evidence concerns the gene SRXN1 and cerebrovascular disorder.